Eli Lilly’s Mounjaro Hits ₹100 Crore in October Sales as Usage Soars for Weight Loss!
Eli Lilly’s Mounjaro Hits ₹100 Crore in October Sales as Usage Soars for Weight Loss!
Dominating India’s pharmaceutical charts, Eli Lilly’s Mounjaro has claimed the title of the country’s highest-selling medicine by value, clocking ₹100 crore in sales during October, according to a Reuters report. The milestone reflects India’s surging demand for modern metabolic treatments, particularly those addressing diabetes and obesity, two of the nation’s fastest-growing health concerns.
Launched in March 2025, Mounjaro has quickly established itself as a market leader among prescription drugs. Data from research firm Pharmarack shows that by the end of October, the product had already generated ₹333 crore in total revenue, outpacing competitors by a considerable margin. In terms of volume, its usage was reportedly ten times higher than Novo Nordisk’s Wegovy, which entered the Indian market three months later in June.
Mounjaro, powered by the active ingredient tirzepatide, is part of a new class of metabolic drugs that act on hormones to help regulate blood sugar levels and promote significant weight reduction. Although it was first approved for type-II diabetes, its strong results in weight management have led to widespread off-label use for treating obesity, turning it into one of the most talked-about drugs in the country’s healthcare space.
To extend its reach beyond major cities, Eli Lilly has teamed up with Cipla to launch the same tirzepatide formulation under a new brand name, Yurpeak. Under this partnership, Lilly will continue to manufacture and supply the product, while Cipla will handle marketing and distribution across both urban and semi-urban areas. Yurpeak will be priced identically to Mounjaro, ensuring that patients have broader access without cost variation. The collaboration marks a strategic move to strengthen tirzepatide’s footprint across India’s expanding obesity and diabetes market.
Meanwhile, Novo Nordisk has received approval from the Central Drugs Standard Control Organisation (CDSCO) to introduce its diabetes drug Ozempic in India. The semaglutide-based injectable was granted authorization on September 26, and though an official launch date has not yet been revealed, industry watchers anticipate its arrival soon. The approval will allow Novo Nordisk to complete its semaglutide portfolio in India, offering a comprehensive range of metabolic treatments. The company’s managing director, Vikrant Shrotriya, stated that Ozempic’s launch will further strengthen Novo Nordisk’s presence in the diabetes-care segment.
Experts estimate the anti-obesity drug market in India to be valued at roughly ₹752 crore, with semaglutide-based therapies alone contributing around ₹426 crore. This growth highlights the accelerating demand for effective weight-loss solutions among Indian patients. However, the high prices of these medications remain a major hurdle. Mounjaro currently costs between ₹14,000 and ₹17,500 per month, depending on dosage, putting it out of reach for a large portion of the population. Despite this, the potential remains vast, given that about 100 million Indians are estimated to be living with diabetes and an equal number with obesity. The dominance of Mounjaro, the expansion through Yurpeak, and the anticipated entry of Ozempic together mark a turning point for India’s healthcare industry.
